Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q2 2021 · 10-Q
Revenue$2.42M$2.42M−35.9% vs Q2 2020 Net Income-$824.76K-$824.76KN/M vs Q2 2020 EPS Diluted-$0.02-$0.02— vs Q2 2020 Gross Profit$71,000−93.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived$676,036+639.5% Margins · derivedGross margin2.9%−27.6 pt vs Q2 2020
Operating margin-31.2%−33.2 pt vs Q2 2020
Net margin-34.1%−34.5 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 13, 2021 · 44 d after period end